Nurix Therapeutics to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Nurix Therapeutics (Nasdaq: NRIX) announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer, will participate in fireside chats at two investor conferences in November 2025:
- Stifel 2025 Healthcare Conference — New York, NY — Thursday, November 13, 2025, 9:20–9:50 a.m. ET
- Jefferies Global Healthcare Conference — London, UK — Wednesday, November 19, 2025, 11:00–11:25 a.m. GMT
The events will be webcast live and accessible via a link in the Investors section of the Nurix website. Archived webcasts will be available for 30 days after each event.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, NRIX gained 9.23%, reflecting a notable positive market reaction. Argus tracked a peak move of +8.3% during that session. Our momentum scanner triggered 73 alerts that day, indicating high trading interest and price volatility. This price movement added approximately $113M to the company's valuation, bringing the market cap to $1.34B at that time.
Data tracked by StockTitan Argus on the day of publication.
SAN FRANCISCO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will participate in fireside chats at the following investor conferences in November.
- Stifel 2025 Healthcare Conference, New York, NY
- Thursday, November 13, 2025, from 9:20 – 9:50 a.m. ET
- Jefferies Global Healthcare Conference – London, UK
- Wednesday, November 19, 2025, from 11:00 – 11:25 a.m. GMT
The fireside chats will be webcast live and can be accessed via a link in the Investors section of the Nurix website. The archived webcasts will be available for 30 days after the event.
About Nurix Therapeutics, Inc.
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Nurix’s wholly owned, clinical stage pipeline includes degraders of Bruton’s tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix also is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Nurix’s partnered drug discovery pipeline consists of a preclinical stage degrader of STAT6 in collaboration with Sanofi, a clinical stage degrader of IRAK4 in collaboration with Gilead, as well as multiple additional programs under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates. Powered by a fully AI-integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease. Nurix is headquartered in San Francisco, California. For additional information visit http://www.nurixtx.com.
Contacts:
Investors
Kris Fortner
Nurix Therapeutics, Inc.
kfortner@nurixtx.com
Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
lwolffe@wheelhouselsa.com
Media
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
Kris Fortner
Nurix Therapeutics
Kfortner@nurixtx.com
FAQ
When will Nurix (NRIX) present at the Stifel 2025 Healthcare Conference?
What time is Nurix (NRIX) scheduled to speak at the Jefferies Global Healthcare Conference in London?
How can investors watch the Nurix (NRIX) fireside chats live?
Will recordings of the Nurix (NRIX) conference presentations be available after the events?
Who will represent Nurix (NRIX) at the November 2025 investor conferences?
Which investor conferences will Nurix (NRIX) attend in November 2025?
